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Background: To evaluate the feasibility and security of complete remission (CR) of advanced hepatocellular carcinoma
(HCC) achieved with sorafenib treatment, and investigate the previously described predictive factors in CR.
Methods: The case of a patient who achieved CR of advanced HCC with sorafenib treatment was analyzed. The case
analysis was performed by a literature review of relevant reports retrieved from the PubMed database.
Results: A 58-year-old male patient achieved CR of advanced HCC after 23 weeks of oral treatment with sorafenib alone
for 41 months and maintained CR for more than 35 months. Eleven reports worldwide have documented a total of
twelve patients who achieved CR of advanced HCC, including six with nonsurgical oral sorafenib treatment, four with
surgical resection in the descent stage following oral sorafenib treatment and two with oral sorafenib treatment for
postoperative metastasis.
Conclusions: For unresectable advanced HCC, sorafenib can significantly improve progression-free survival and overall
survival, achieving CR in some cases. In addition, surgical resection of advanced HCC in the descent stage is possible
following oral sorafenib treatment. For patients with postoperative distant metastasis of HCC, sorafenib treatment also
provides clinical benefits and can even achieve CR. Besides, long-term sorafenib administration is safe, and patients
should continually receive sorafenib to avoid recurrence after complete remission of cancer. Furthermore, early HFSR,
rapid decline of AFP levels and rapid tumor shrinking observed by imaging are known parameters describing sorafenib’s
effects. Finally, it is important to assess the gene locus of sorafenib sensitivity in HCC patients in future research.
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Hepatocellular carcinoma (HCC) constitutes 90% of pri-
mary liver cancer (PLC), which is the fifth most common
malignant tumor and the third major cause of cancer-
related deaths worldwide. In recent years, the global inci-
dence of HCC has gradually increased, with more than
620,000 new patients currently diagnosed yearly. However,
only 20% of patients with HCC can receive curative local
treatment such as surgical resection, liver transplantation,
and radiofrequency ablation, among others. In addition,
the vast majority of patients present to the clinic with
advanced stage disease; these patients typically die within
three to six months as a result of lack of effective treat-
ment [1]. Consequently, advanced HCC is known for its
poor prognosis.* Correspondence: liuaixiangcd@163.com; schpjp@163.com
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unless otherwise stated.Sorafenib is a small-molecule multikinase inhibitor that
mainly inhibits kinases including Raf kinase, vascular endo-
thelial growth factor receptor (VEGFR), and platelet-
derived growth factor receptor (PDGFR). Two randomized,
double-blinded, controlled large phase III clinical trials, the
SHARP (Sorafenib HCC Assessment Randomized Protocol
trial) and the Asia-Pacific (conducted in the Asia-Pacific
region) trials clearly demonstrated that sorafenib is
currently the only systemic agent, not only improving
progression-free survival significantly, but also enhancing
overall survival in patients with unresectable advanced
HCC [2,3]. Unfortunately, a complete remission (CR) was
not achieved in patients of the sorafenib group, indicating
that achieving CR is rare after sorafenib treatment.
In this study, we present a case of advanced HCC asso-
ciated with portal vein tumor thrombosis; the patient was
treated with sorafenib alone for 41 months and achieved
CR that was maintained for more than 35 months. Onlys is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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achieved CR after sorafenib administration. To the best of
our knowledge, the case reported here represents the
longest documented sustained CR of primary liver lesions
with sorafenib treatment; it is also the longest administra-
tion time recorded. The 12 previous cases of CR were
assessed to explore the feasibility and security of CR and
the previously described predictive factors.
Case presentation
The patient was a 58-year-old male, who had fatigue and
discomfort without obvious incentive in 1990. This
patient had no other discomforts such as fever, vomiting,
abdominal pain or diarrhea. Neither xanthochromia nor
icteric sclera was detected. After being admitted into a
local hospital, the patient was diagnosed with a hepatitis
B virus (HBV) infection following detection of hepatitis
B and elevated transaminase levels. His condition improved
upon hospitalization and treatment. In 1997, the HBV
marker was negative and liver function normal.
During a routine examination in 2008, this patient had
an elevated alpha-fetoprotein (AFP, which is the specific
tumor marker of HCC) level of 56 IU/ml (normal level
0 to 8 IU/ml). Computed tomography (CT) scans
showed the presence of cirrhosis, splenomegaly, and a
0.9 cm × 0.8 cm small nodule of an undetermined nature
in the right liver lobe. The patient was consequently given
a diagnostic intervention of a focal liver lesion under local
anesthesia by transcatheter hepatic arterial chemoemboli-
zation (TACE) on November 19, 2008 (drugs adminis-
tered included: epirubicin, 20 mg; hydroxycamptothecine,
20 mg and ultra-fluid lipiodol, 3 ml). No positive marker
was detected during the surgery and anti-inflammatory,
liver-protective and symptomatic treatment was given
postoperatively.
Four days after the surgery, the patient’s AFP level
declined to 92.64 ng/ml (normal level 0 to 20 ng/ml). On
January 13, 2009, the reexamination results revealed that
the AFP level had slightly increased to 224.55 ng/ml. CT
scans demonstrated the presence of a small 1.9 cm ×
1.4 cm sheet-like low-density shallow in the left lobe ofFigure 1 The tumor shrank step by step during early sorafenib treatm
6.3 cm; (b) week 5 of targeted therapy, tumor size decreased by 39.8%; (c)liver, the nature of which was yet to be determined.
Contrast ultrasonography data indicated the presence of a
hypoechoic nodule in the left liver, supporting the diagno-
sis of a small HCC. The patient consequently underwent
radiofrequency ablation (RFA) surgery on January 19,
2009 (needle length, 4 cm; temperature, 105°C; voltage,
150 V; treatment time, 10 min). A month later, the AFP
level dropped to a normal level (15.43 ng/ml).
During follow-up, the patient’s AFP level elevated to
29.25 ng/ml on April 22, 2009. Contrast ultrasonography
data showed that the arterial phase on the top right of
the primary tumor was significantly enhanced. As the
disease can reoccur after the first RFA, the patient
underwent a second RFA surgery on April 24, 2009 (needle
length, 5 cm; temperature, 105°C; voltage, 150 V; treatment
time, 10 min), followed by two TACE surgeries on May 4
and September 14, 2009, respectively (drugs administered
included: epirubicin, 40 mg; hydroxycamptothecin (HCPT),
20 mg and ultra-fluid lipiodol, 10 ml). Postoperative follow-
up data showed that the patient was disease free.
On October 25, 2010, the patient was reexamined in
Sichuan Cancer Hospital. The AFP level was found to be
significantly high at 51.750 ng/ml. Magnetic resonance
imaging (MRI) scans showed that the liver had multiple
masses (maximal size, 5.4 cm × 7.9 cm) associated with
portal vein tumor thrombosis (lesion fusion range,
7.7 cm × 7.9 cm × 6.3 cm; Figure 1a). The examination
data from outpatient services showed that the patient’s
physical condition was generally good (Eastern Cooperative
Oncology Group (ECOG) score, 0), with no xanthochromia
or icteric sclera, no positive signs of illness and no ascites.
The blood coagulation function was normal, and liver
function was ranked to Child-Pugh A (Child-Pugh is the
grading standard of liver functional assessment, and for
the choice of treatment plan provides an important refer-
ence). Accordingly, the patient was diagnosed with ad-
vanced HCC, classified as stage C of the Barcelona clinical
liver cancer staging system.
From October 26, 2010, the patient received outpatient
treatment of daily oral sorafenib. The initial dose of oral
sorafenib was 800 mg/day, twice daily (morning andent. (a) Before targeted therapy, tumor size was 7.7 cm × 7.9 cm ×
week 15 of targeted therapy, tumor size decreased by 96.9%.
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skin reaction (HFSR) with persistent diarrhea (four to six
times daily). As a result, the dose of oral sorafenib was
adjusted to 400 mg/day (twice daily). The HFSR symp-
toms were treated with urea ointment, aloe cream, and
emollient cream by local topical therapy. The diarrhea was
treated by oral administration of smectite and loperamide
hydrochloride The above symptoms were gradually allevi-
ated after appropriate symptomatic treatments. The dose
of oral sorafenib was adjusted to 600 mg/day (twice daily)
from week 15 and then restored to the standard dose of
800 mg/day from week 23. A follow-up was conducted by
strictly following the assistance project requirement of
the China Charity Federation. The outpatient reexami-
nation involved monthly examinations of AFP levels, liver
function, and blood coagulation function, with bimonthly
examinations by MRI.
Follow-up data showed that the HFSR and diarrhea
were alleviated after oral sorafenib treatment for six
months and the patient engaged in daily life and work
during treatment. In week 5, MRI scans showed that the
size of the tumor lesion declined by 39.8% to 7.5 cm ×
5.4 cm × 5.7 cm; necrosis occurred in partial tissues of the
tumor mass, as indicated by a clearer edge (Figure 1b);
and AFP levels declined by more than 50%. In week 15,
MRI scans showed that the size of tumor lesion declined
by more than 96.9% to 2.8 cm × 1.7 cm × 2 cm; there was
no tumor activity in the artery phase (Figure 1c); and the
AFP level was close to the normal range, 54.33 ng/ml. In
week 23, MRI scans showed that the tumor mass had
completely disappeared (Figure 2a), and the AFP level
had decreased to a normal level (Table 1). According the
Response Evaluation Criteria In Solid Tumors (RECIST)
criteria, the tumor examined by MRI had completely
disappeared over four weeks, suggesting the achieve-
ment of CR.
To date, MRI examination shows that the tumor had
completely disappeared in the patient over a period of
35 months. During follow-up, no radiographic evidence
indicated the recurrence of HCC (Figure 2b,c), and theFigure 2 Follow-up after complete remission achieved, there is no rec
completely disappeared; (b) year 2 of targeted therapy, the tumor has com
completely disappeared.AFP level remained within the normal range. The patient
was engaged in normal daily life and work and achieved
sustained CR of advanced HCC.
Literature review
Relevant reports were searched and retrieved manually
from the PubMed database. Since the availability in 2007
of sorafenib for treatment of advanced HCC, a total of
11 reports worldwide have documented 12 patients who
achieved CR of advanced HCC with this therapy [4-14]
(Table 2).
Discussion
Sorafenib is a small-molecule multikinase inhibitor that
primarily inhibits Raf kinase, VEGFR, and PDGFR. It is
unique in targeting the Raf/Mek/Erk (MAP Kinase) path-
way [15], as HCC mainly involves overexpression of the
RAF/MEK/ERK pathway [16] In addition, extracellular
activation of VEGFR and PDGFR are involved in the
formation of HCC and portal vein tumor thrombosis. It is
assumed that sorafenib has dual activity by both inhibiting
tumor cell proliferation as well as tumor angiogenesis
[17]. Two large stage III clinical trials, the SHARP trial
and the Asia Pacific trial, reported that sorafenib adminis-
tration increases the survival time of advanced HCC,
however neither trial achieved CR in cases of advanced
HCC [2,3].
During the literature search, only 11 reports were
found worldwide that had documented 12 patients with
CR of advanced HCC since the introduction of sorafenib
for the treatment of advanced HCC in 2007. The twelve
cases of CR included six with nonsurgical oral sorafenib
treatment, four with surgical resection in the descent
stage following oral sorafenib treatment [6,9,13] and two
with oral sorafenib treatment for postoperative metastasis
[5,12]. In the present study, the case of a 58-year-old male
patient who achieved CR of advanced HCC associated
with portal vein tumor thrombosis is reported. In this
patient, CR was achieved after 23 weeks of oral sorafenib
treatment; he was treated with sorafenib alone for aurrence of tumor. (a) Week 23 of targeted therapy, the tumor has
pletely disappeared; (c) year 3 of targeted therapy, the tumor has
Table 1 Dynamic changes in alpha-fetoprotein (AFP) level of the patient with advanced hepatocellular carcinoma
before and after sorafenib treatment
Detection time Detection method AFP (ng/ml) Assessment
2010.10.25 Chemiluminescence 51750.00 Normal range, 0–20 ng/ml
2010.11.29 Chemiluminescence 21668.00 Decrease by >50% in week 5
2011.02.16 Chemiluminescence 54.33 Close to normal in week 15
2011.04.14 Chemiluminescence <10 Normal in week 23
2011.05.18–13.11.12 Chemiluminescence <10 Normal for >30 months
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35 months. To the best of our knowledge, it is the longest
documented sustained CR of primary liver lesions with
sorafenib treatment; it is also the longest administration
time recorded. The results of this case analysis demon-
strate that for unresectable advanced HCC, sorafenib
treatment can significantly improve progression-free
survival and overall survival, achieving CR in some
cases. In addition, sorafenib treatment enables surgical
resection of the tumor lesion in the descent stage of
advanced HCC. In cases of postoperative distant metas-
tasis of HCC, administration of sorafenib also provides
clinical benefits and can even achieve CR.
In the reports reviewed in this manuscript, the cases
of CR lacked definite pathological diagnosis. Among the
six patients with nonsurgical oral sorafenib treatment,
only one was diagnosed as HCC by liver biopsy whilst the
other five patients had no pathological diagnosis. Of these,
two were diagnosed with HCC by positron emission
tomography (PET)-CT, and the remaining three patients
shared the following three common characteristics: (1) a
history of hepatitis; (2) typical imaging findings of HCC;
and (3) abnormally elevated AFP, which returned to
normal after treatment with sorafenib. It is known that in
the Asia Pacific, the majority of HCC patients have a back-
ground of liver cirrhosis, the specificity of typical imaging
findings, combined with the criterion of AFP >400 ng/ml
resulting in HCC diagnosis of close to 100% [18]. In the
case reported in this present study (this 58-year-old male
patient), both the continuous shrinking of tumor size in
the MRI scans and the rapidly decreasing AFP levels
during sorafenib treatment indicate that the CR of ad-
vanced HCC was induced by sorafenib. This case meets
the diagnostic criteria for advanced HCC. For advanced
HCC patients under nonsurgical oral sorafenib treatment,
MRI imaging diagnosis combined with the criterion of
AFP >400 ng/ml provides an objective indicator for HCC
diagnosis and therapeutic assessment.
The most common adverse reactions of sorafenib
comprise rash, diarrhea, HFSR, fatigue, and alopecia.
Other adverse reactions include nausea and vomiting,
anorexia, and hypertension [19]. However, these adverse
reactions can be easily controlled, and patients seemed
to well tolerate the drug in the SHARP and Asia Pacifictrials [2,3]. Our patient had excellent adherence to the
medication and did not terminate oral sorafenib even
with severe HFSR and diarrhea. This patient continued
sorafenib medication under appropriate symptomatic
treatments. This is in contrast to the patients included
in the SHARP trial, where the discontinuation rate of
medication was up to 36% [2]. Most cases of CR were
discontinued from taking sorafenib because of economic
reasons and/or the drug’s adverse effects. However, it is
unknown whether CR is maintained following discon-
tinuation. The patient reported here continued sorafenib
treatment after he had achieved CR. To date (March 25,
2014), around 41 treatment months have been sustained.
His quality of life has not been affected and other indica-
tors such as liver function are normal: he lives a normal
life and works without problem. Therefore, long-term
drug use seems safe, and HCC patients should continue
to receive sorafenib after CR to avoid recurrence.
Studies show that early HFSR [20] and the rapid
decline of AFP levels [21] are indicative of the antitumor
activity of sorafenib, thus supporting the good thera-
peutic effects of sorafenib on HCC patients. These two
parameters can therefore be used as early indicators for
predicting the therapeutic effects of sorafenib treatment,
which will help to adjust the treatment plan. Our patient
had severe HFSR after three days of medication; mean-
while, his AFP level decreased rapidly to more than
50% in early treatment. These findings are supported by
previous works. Not only that, MRI scans showed rapid
shrinkage of the tumor size during early sorafenib treat-
ment (39.8% in week 5 and by 96.9% in week 15), which
indicated that rapid tumor shrinking on the imaging
may be another indicator of the therapeutic effects of
sorafenib.
HCC has unique molecular biological characteristics.
Targets of sorafenib, including Raf kinase, VEGFR and
PDGFR are not expressed on all HCC, which explains
why CR of advanced HCC is rare after treatment with
sorafenib. If the gene locus of sorafenib sensitivity in
HCC could be assessed in HCCs, patients might be able
to receive individualized treatments, which perhaps
would lead to more individuals achieving CR. Although
the lack of biopsy prevented us from exploring the case
at the molecular level, we believe this case is of great
Table 2 Case summary of complete remission (CR) of advanced hepatocellular carcinoma achieved by sorafenib treatment













1 78, male Lung 400 5 6 17/10/08 Journal of Hematology &
Oncology
So et al. [4] First case of CR
2 54, male Lung 400 18 Unknown 1/9/09 American Journal of Transplantation Yeganeh et al. [5] Solitary pulmonary metastasis
post liver transplantation
3 59, male Portal vein 400 6 16 14/3/10 Liver International ISSN Irtan et al. [6] Two cases reported in the same report;
CR achieved by surgical resection in the
descent stage following sorafenib treatment.4 57, male Portal vein 400 6 12 14/3/10 Liver International ISSN Irtan et al. [6]
5 74, male Portal vein 200 8 16 23/3/10 Targeted Oncology Wang et al. [7] Initial dose at a low level
6 67, male Portal lymph node 400 6 6 31/8/10 Medical Oncology Chelis et al. [8] HIV-hepatitis B virus (HBV) co-infected
with advanced hepatocellular carcinoma
7 56, male Thoracic diaphragm 400 6 6 20/4/11 Journal of Clinical Oncology Curtit et al. [9] CR achieved by surgical resection in the
descent stage following sorafenib treatment.
8 84, male Portal vein 400 6 6 11/4/11 BMC Gastroenterology Sacco et al. [10] First case of CR in hepatitis C patients
in older people
9 76, female Lung 200 4 8 22/12/11 Oncology Inuzuka et al. [11] First female case
10 60, male Portal lymph node 400 11 days 12 24/7/12 Oncology Mizukami et al. [12] Shortest time to achieve CR
11 52, male Lung 400 6 42 10/10/12 Journal of Gastrointestinal Cancer Lulla et al. [13] Longest duration of CR
12 66, male Portal vein 400 6 8 15/2/13 World Journal of
Gastrointestinal Oncology












Liu et al. European Journal of Medical Research  (2015) 20:12 Page 6 of 6value, providing evidence of individual cancer biology,
which merits further investigation.
Conclusions
In conclusion, for unresectable advanced HCC, sorafenib
can significantly improve progression-free survival and
overall survival, achieving CR in some cases. In addition,
surgical resection of advanced HCC in the descent stage
is possible following oral sorafenib treatment. For patients
with postoperative distant metastasis of HCC, sorafenib
treatment also provides clinical benefits and can even
achieve CR. The adverse reactions of sorafenib are pre-
dictable. Patients might get clinical benefits and even
achieve CR by adopting reasonable and accurate measures
for the early sorafenib adverse reactions; this could
increase patient’s willingness during treatment to continue
sorafenib medication. We consider sorafenib very safe for
long-term administration, which can prevent recurrence
after CR. Furthermore, early HFSR, rapid decline of AFP
levels and rapid tumor shrinking are the previously
observed parameters of sorafenib’s curative effects. Finally,
future research is necessary to assess the gene locus of
sorafenib sensitivity in HCC.
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